These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15981032)

  • 21. Clinical efficacy of oral risedronate therapy in Japanese patients with Paget's disease of bone.
    Ohara M; Imanishi Y; Nagata Y; Ishii A; Kobayashi I; Mori K; Ito M; Miki T; Nishizawa Y; Inaba M
    J Bone Miner Metab; 2015 Sep; 33(5):584-90. PubMed ID: 25319558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of bone.
    Garnero P; Christgau S; Delmas PD
    Bone; 2001 May; 28(5):461-4. PubMed ID: 11344044
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multicenter trial of low dose gallium nitrate in patients with advanced Paget's disease of bone.
    Bockman RS; Wilhelm F; Siris E; Singer F; Chausmer A; Bitton R; Kotler J; Bosco BJ; Eyre DR; Levenson D
    J Clin Endocrinol Metab; 1995 Feb; 80(2):595-602. PubMed ID: 7852526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of methotrexate on bone metabolism markers in patients with rheumatoid arthritis.
    Torikai E; Kageyama Y; Takahashi M; Nagano A
    Mod Rheumatol; 2006; 16(6):350-4. PubMed ID: 17164995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paget's disease: a case in point.
    Nivens AS
    Orthop Nurs; 2004; 23(6):355-61; quiz 362-3. PubMed ID: 15682878
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of Paget's disease of bone with alendronate.
    Lombardi A
    Bone; 1999 May; 24(5 Suppl):59S-61S. PubMed ID: 10321931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial.
    Chevrel G; Schott AM; Fontanges E; Charrin JE; Lina-Granade G; Duboeuf F; Garnero P; Arlot M; Raynal C; Meunier PJ
    J Bone Miner Res; 2006 Feb; 21(2):300-6. PubMed ID: 16418786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decreased beta-isomerization of the C-terminal telopeptide of type I collagen alpha 1 chain in Paget's disease of bone.
    Garnero P; Fledelius C; Gineyts E; Serre CM; Vignot E; Delmas PD
    J Bone Miner Res; 1997 Sep; 12(9):1407-15. PubMed ID: 9286756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of Paget's disease of bone.
    Langston AL; Ralston SH
    Rheumatology (Oxford); 2004 Aug; 43(8):955-9. PubMed ID: 15187244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
    Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
    Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of alendronate treatment on the clinical picture and bone turnover markers in chronic idiopathic hyperphosphatasia.
    Demir E; Bereket A; Ozkan B; Topçu M
    J Pediatr Endocrinol Metab; 2000 Feb; 13(2):217-21. PubMed ID: 10711670
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Markers of bone resorption in bisphosphonate therapy of Paget's disease.
    Cacace E; Ruggiero V; Matulli C; Uras L; Perpignano G
    Clin Exp Rheumatol; 2004; 22(4):502. PubMed ID: 15301254
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.
    Peris P; Alvarez L; Vidal S; Martínez MA; Monegal A; Guañabens N
    Clin Exp Rheumatol; 2007; 25(2):206-10. PubMed ID: 17543143
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy.
    Cundy T; Wheadon L; King A
    J Bone Miner Res; 2004 May; 19(5):703-11. PubMed ID: 15068492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Chromatographic analysis of urinary amino acids in Paget's disease. II : clinical study].
    Roques CF; Mazières B; Amigues H; Fournie A; Arlet J; Ruffié R
    Rev Rhum Mal Osteoartic; 1976 Apr; 43(4):255-8. PubMed ID: 1273475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate.
    O'Doherty DP; Bickerstaff DR; McCloskey EV; Hamdy NA; Beneton MN; Harris S; Mian M; Kanis JA
    J Bone Miner Res; 1990 May; 5(5):483-91. PubMed ID: 2195845
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Diagnosis and management of Paget's disease of bone].
    Hashimoto J; Yoshikawa H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():56-64. PubMed ID: 18161082
    [No Abstract]   [Full Text] [Related]  

  • 38. Short-term therapy with oral olpadronate in active Paget's disease of bone.
    González DC; Mautalen CA
    J Bone Miner Res; 1999 Dec; 14(12):2042-7. PubMed ID: 10620063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Short-term risedronate treatment in postmenopausal women: effects on biochemical markers of bone turnover.
    Raisz L; Smith JA; Trahiotis M; Fall P; Shoukri K; Digennaro J; Sacco-Gibson N
    Osteoporos Int; 2000; 11(7):615-20. PubMed ID: 11069196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paget's disease of bone in a patient on hemodialysis.
    Etemadi J; Bagheri N; Falaknazi K; Ardalan M; Rahbar K; Nobakht Haghighi A; Mohajel Shoja M
    Iran J Kidney Dis; 2008 Apr; 2(2):105-7. PubMed ID: 19377219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.